{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:33:15Z","timestamp":1772119995297,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T00:00:00Z","timestamp":1646352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T00:00:00Z","timestamp":1646352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Brain Foundation"},{"name":"Kids Cancer Project"},{"DOI":"10.13039\/501100001249","name":"University of Tasmania","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001249","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001249","name":"University of Tasmania","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001249","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Medulloblastoma (MB) is the most common malignant paediatric brain tumour. In our previous studies, we developed a novel 3D assay for MB cells that was used to screen a panel of plasma membrane calcium channel modulators for their effect on the 3D growth of D341 MB cells. These studies identified T-type (CaV3) channel inhibitors, mibefradil and NNC-55\u20130396 (NNC) as selective inhibitors of MB cell growth. Mibefradil was originally approved for the treatment of hypertension and angina pectoris, and recently successfully completed a phase I trial for recurrent high-grade glioma. NNC is an analogue of mibefradil with multiple advantages compared to mibefradil that makes it attractive for potential future clinical trials. T-type channels have a unique low voltage-dependent activation\/inactivation, and many studies suggest that they have a direct regulatory role in controlling Ca\n                    <jats:sup>2+<\/jats:sup>\n                    signalling in non-excitable tissues, including cancers. In our previous study, we also identified overexpression of CaV3.2 gene in MB tissues compared to normal brain tissues. In this study, we aimed to characterise the effect of mibefradil and NNC on MB cells and elucidate their mechanism of action. This study demonstrates that the induction of toxicity in MB cells is selective to T-type but not to L-type Ca\n                    <jats:sup>2+<\/jats:sup>\n                    channel inhibitors. Addition of CaV3 inhibitors to vincristine sensitised MB cells to this MB chemotherapeutic agent, suggesting an additive effect. Furthermore, CaV3 inhibitors induced cell death in MB cells via apoptosis. Supported by proteomics data and cellular assays, apoptotic cell death was associated with reduced mitochondrial membrane potential and reduced ATP levels, which suggests that both compounds alter the metabolism of MB cells. This study offers new insights into the action of mibefradil and NNC and will pave the way to test these molecules or their analogues in pre-clinical MB models alone and in combination with vincristine to assess their suitability as a potential MB therapy.\n                  <\/jats:p>","DOI":"10.1007\/s12035-022-02771-0","type":"journal-article","created":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T20:02:30Z","timestamp":1646337750000},"page":"2932-2945","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["T-Type Calcium Channel Inhibitors Induce Apoptosis in Medulloblastoma Cells Associated with Altered Metabolic Activity"],"prefix":"10.1007","volume":"59","author":[{"given":"Mohammed","family":"Sedeeq","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Maklad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taush","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zikai","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuri","family":"Gueven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9477-9999","authenticated-orcid":false,"given":"Iman","family":"Azimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,4]]},"reference":[{"issue":"6","key":"2771_CR1","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00401-016-1569-6","volume":"131","author":"V Ramaswamy","year":"2016","unstructured":"Ramaswamy V, Remke M, Bouffet E, Bailey S, Clifford SC, Doz F, Kool M, Dufour C et al (2016) Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathol 131(6):821\u2013831","journal-title":"Acta Neuropathol"},{"issue":"3","key":"2771_CR2","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s11060-004-3009-z","volume":"72","author":"AM Maddrey","year":"2005","unstructured":"Maddrey AM, Bergeron JA, Lombardo ER, McDonald NK, Mulne AF, Barenberg PD, Bowers DC (2005) Neuropsychological performance and quality of life of 10 year survivors of childhood medulloblastoma. J Neurooncol 72(3):245\u2013253","journal-title":"J Neurooncol"},{"issue":"6","key":"2771_CR3","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nrc.2017.18","volume":"17","author":"GR Monteith","year":"2017","unstructured":"Monteith GR, Prevarskaya N, Roberts-Thomson SJ (2017) The calcium\u2013cancer signalling nexus. Nat Rev Cancer 17(6):373\u2013380","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2771_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.apsb.2016.11.001","volume":"7","author":"C Cui","year":"2017","unstructured":"Cui C, Merritt R, Fu L, Pan Z (2017) Targeting calcium signaling in cancer therapy. Acta pharmaceutica sinica B 7(1):3\u201317","journal-title":"Acta pharmaceutica sinica B"},{"issue":"32","key":"2771_CR5","doi-asserted-by":"publisher","first-page":"4984","DOI":"10.3748\/wjg.14.4984","volume":"14","author":"JT Taylor","year":"2008","unstructured":"Taylor JT, Zeng X-B, Pottle JE, Lee K, Wang AR, Yi SG, Scruggs JAS, Sikka SS et al (2008) Calcium signaling and T-type calcium channels in cancer cell cycling. World J Gastroenterol 14(32):4984","journal-title":"World J Gastroenterol"},{"issue":"4","key":"2771_CR6","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1111\/j.1476-5381.2012.01908.x","volume":"166","author":"G Santoni","year":"2012","unstructured":"Santoni G, Santoni M, Nabissi M (2012) Functional role of T-type calcium channels in tumour growth and progression: Prospective in cancer therapy. Br J Pharmacol 166(4):1244\u20131246","journal-title":"Br J Pharmacol"},{"issue":"2","key":"2771_CR7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ceca.2006.04.014","volume":"40","author":"LS Gray","year":"2006","unstructured":"Gray LS, Macdonald TL (2006) The pharmacology and regulation of T type calcium channels: new opportunities for unique therapeutics for cancer. Cell Calcium 40(2):115\u2013120","journal-title":"Cell Calcium"},{"issue":"9","key":"2771_CR8","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.3390\/genes12091329","volume":"12","author":"A Maklad","year":"2021","unstructured":"Maklad A, Sedeeq M, Milevskiy MJ, Azimi I (2021) Calcium Signalling in Medulloblastoma: An In Silico Analysis of the Expression of Calcium Regulating Genes in Patient Samples. Genes 12(9):1329","journal-title":"Genes"},{"issue":"11","key":"2771_CR9","doi-asserted-by":"publisher","first-page":"368","DOI":"10.3390\/ph13110368","volume":"13","author":"M Sedeeq","year":"2020","unstructured":"Sedeeq M, Maklad A, Gueven N, Azimi I (2020) Development of a high-throughput agar colony formation assay to identify drug candidates against medulloblastoma. Pharmaceuticals 13(11):368","journal-title":"Pharmaceuticals"},{"issue":"13","key":"2771_CR10","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1158\/0008-5472.CAN-16-2347","volume":"77","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Cruickshanks N, Yuan F, Wang B, Pahuski M, Wulfkuhle J, Gallagher I, Koeppel AF et al (2017) Targetable T-type calcium channels drive glioblastoma. Can Res 77(13):3479\u20133490","journal-title":"Can Res"},{"issue":"6","key":"2771_CR11","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1093\/neuonc\/nox020","volume":"19","author":"M Holdhoff","year":"2017","unstructured":"Holdhoff M, Ye X, Supko JG, Nabors LB, Desai AS, Walbert T, Lesser GJ, Read WL et al (2017) Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas. Neuro Oncol 19(6):845\u2013852","journal-title":"Neuro Oncol"},{"issue":"1","key":"2771_CR12","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1124\/jpet.103.060814","volume":"309","author":"L Huang","year":"2004","unstructured":"Huang L, Keyser BM, Tagmose TM, Hansen JB, Taylor JT, Zhuang H, Zhang M, Ragsdale DS et al (2004) NNC 55\u20130396 [(1S, 2S)-2-(2-(N-[(3-benzimidazol-2-yl) propyl]-N-methylamino) ethyl)-6-fluoro-1, 2, 3, 4-tetrahydro-1-isopropyl-2-naphtyl cyclopropanecarboxylate dihydrochloride]: a new selective inhibitor of T-type calcium channels. J Pharmacol Exp Ther 309(1):193\u2013199","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"2771_CR13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ejphar.2011.01.004","volume":"659","author":"A Quesada","year":"2011","unstructured":"Quesada A, Bui PH, Homanics GE, Hankinson O, Handforth A (2011) Comparison of mibefradil and derivative NNC 55\u20130396 effects on behavior, cytochrome P450 activity, and tremor in mouse models of essential tremor. Eur J Pharmacol 659(1):30\u201336","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"2771_CR14","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41596-018-0082-x","volume":"14","author":"CS Hughes","year":"2019","unstructured":"Hughes CS, Moggridge S, M\u00fcller T, Sorensen PH, Morin GB, Krijgsveld J (2019) Single-pot, solid-phase-enhanced sample preparation for proteomics experiments. Nat Protoc 14(1):68\u201385","journal-title":"Nat Protoc"},{"issue":"23","key":"2771_CR15","doi-asserted-by":"publisher","first-page":"7537","DOI":"10.1007\/s00018-021-03955-y","volume":"78","author":"C Espejo","year":"2021","unstructured":"Espejo C, Wilson R, Willms E, Ruiz-Aravena M, Pye RJ, Jones ME, Hill AF, Woods GM et al (2021) Extracellular vesicle proteomes of two transmissible cancers of Tasmanian devils reveal tenascin-C as a serum-based differential diagnostic biomarker. Cell Mol Life Sci 78(23):7537\u20137555","journal-title":"Cell Mol Life Sci"},{"issue":"5","key":"2771_CR16","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1074\/mcp.M114.044305","volume":"14","author":"R Bruderer","year":"2015","unstructured":"Bruderer R, Bernhardt OM, Gandhi T, Miladinovi\u0107 SM, Cheng L-Y, Messner S, Ehrenberger T, Zanotelli V et al (2015) Extending the Limits of Quantitative Proteome Profiling with Data-Independent Acquisition and Application to Acetaminophen-Treated Three-Dimensional Liver Microtissues*[S]. Mol Cell Proteomics 14(5):1400\u20131410","journal-title":"Mol Cell Proteomics"},{"issue":"D1","key":"2771_CR17","doi-asserted-by":"publisher","first-page":"D394","DOI":"10.1093\/nar\/gkaa1106","volume":"49","author":"H Mi","year":"2021","unstructured":"Mi H, Ebert D, Muruganujan A, Mills C, Albou L-P, Mushayamaha T, Thomas PD (2021) PANTHER version 16: a revised family classification, tree-based classification tool, enhancer regions and extensive API. Nucleic Acids Res 49(D1):D394\u2013D403","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"2771_CR18","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","volume":"25","author":"L Galluzzi","year":"2018","unstructured":"Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L et al (2018) Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ 25(3):486\u2013541","journal-title":"Cell Death Differ"},{"issue":"1","key":"2771_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1756-9966-30-87","volume":"30","author":"RS Wong","year":"2011","unstructured":"Wong RS (2011) Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res 30(1):1\u201314","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"2771_CR20","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1158\/0008-5472.CAN-03-1101","volume":"64","author":"R Rossignol","year":"2004","unstructured":"Rossignol R, Gilkerson R, Aggeler R, Yamagata K, Remington SJ, Capaldi RA (2004) Energy substrate modulates mitochondrial structure and oxidative capacity in cancer cells. Can Res 64(3):985\u2013993","journal-title":"Can Res"},{"key":"2771_CR21","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/0076-6879(95)60154-6","volume":"260","author":"M Reers","year":"1995","unstructured":"Reers M, Smiley ST, Mottola-Hartshorn C, Chen A, Lin M, Chen LB (1995) [29] Mitochondrial membrane potential monitored by JC-1 dye. Methods Enzymol 260:406\u2013417","journal-title":"Methods Enzymol"},{"issue":"2","key":"2771_CR22","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1152\/physrev.1990.70.2.391","volume":"70","author":"JG McCORMACK","year":"1990","unstructured":"McCORMACK JG, Halestrap AP, Denton RM (1990) Role of calcium ions in regulation of mammalian intramitochondrial metabolism. Physiol Rev 70(2):391\u2013425","journal-title":"Physiol Rev"},{"issue":"6","key":"2771_CR23","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.bpj.2016.04.054","volume":"111","author":"J Suzuki","year":"2016","unstructured":"Suzuki J, Kanemaru K, Iino M (2016) Genetically encoded fluorescent indicators for organellar calcium imaging. Biophys J 111(6):1119\u20131131","journal-title":"Biophys J"},{"issue":"1","key":"2771_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-015-0171-4","volume":"34","author":"W Huang","year":"2015","unstructured":"Huang W, Lu C, Wu Y, Ouyang S, Chen Y (2015) T-type calcium channel antagonists, mibefradil and NNC-55-0396 inhibit cell proliferation and induce cell apoptosis in leukemia cell lines. J Exp Clin Cancer Res 34(1):1\u201315","journal-title":"J Exp Clin Cancer Res"},{"issue":"7","key":"2771_CR25","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1016\/S0735-1097(99)00447-7","volume":"34","author":"RP Mason","year":"1999","unstructured":"Mason RP (1999) Calcium channel blockers, apoptosis and cancer: is there a biologic relationship? J Am Coll Cardiol 34(7):1857\u20131866","journal-title":"J Am Coll Cardiol"},{"issue":"6805","key":"2771_CR26","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/35037710","volume":"407","author":"MO Hengartner","year":"2000","unstructured":"Hengartner MO (2000) The biochemistry of apoptosis. Nature 407(6805):770\u2013776","journal-title":"Nature"},{"issue":"33","key":"2771_CR27","doi-asserted-by":"publisher","first-page":"22932","DOI":"10.1074\/jbc.274.33.22932","volume":"274","author":"AH Boulares","year":"1999","unstructured":"Boulares AH, Yakovlev AG, Ivanova V, Stoica BA, Wang G, Iyer S, Smulson M (1999) Role of poly (ADP-ribose) polymerase (PARP) cleavage in apoptosis: caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells. J Biol Chem 274(33):22932\u201322940","journal-title":"J Biol Chem"},{"issue":"1","key":"2771_CR28","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ceca.2010.07.001","volume":"48","author":"RI Fonteriz","year":"2010","unstructured":"Fonteriz RI, de la Fuente S, Moreno A, Lobat\u00f3n CD, Montero M, Alvarez J (2010) Monitoring mitochondrial [Ca2+] dynamics with rhod-2, ratiometric pericam and aequorin. Cell Calcium 48(1):61\u201369","journal-title":"Cell Calcium"},{"issue":"4","key":"2771_CR29","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0733-8619(18)30259-7","volume":"9","author":"DR Macdonald","year":"1991","unstructured":"Macdonald DR (1991) Neurologic complications of chemotherapy. Neurol Clin 9(4):955\u2013967","journal-title":"Neurol Clin"},{"issue":"6","key":"2771_CR30","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1055\/s-0029-1238278","volume":"221","author":"A von Bueren","year":"2009","unstructured":"von Bueren A, Von Hoff K, Benesch M, Rutkowski S (2009) Dose reductions of vincristine in children with medulloblastoma treated in the maintenance arm of the prospective multicenter trial HIT\u201991. Klin Padiatr 221(6):396\u2013397","journal-title":"Klin Padiatr"},{"issue":"12","key":"2771_CR31","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.1158\/0008-5472.CAN-15-2104","volume":"76","author":"A Kothari","year":"2016","unstructured":"Kothari A, Hittelman WN, Chambers TC (2016) Cell cycle\u2013dependent mechanisms underlie vincristine-induced death of primary acute lymphoblastic leukemia cells. Can Res 76(12):3553\u20133561","journal-title":"Can Res"},{"issue":"2","key":"2771_CR32","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s11060-012-0995-0","volume":"111","author":"ST Keir","year":"2013","unstructured":"Keir ST, Friedman HS, Reardon DA, Bigner DD, Gray LA (2013) Mibefradil, a novel therapy for glioblastoma multiforme: cell cycle synchronization and interlaced therapy in a murine model. J Neurooncol 111(2):97\u2013102","journal-title":"J Neurooncol"},{"issue":"12","key":"2771_CR33","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.2174\/0929867043365008","volume":"11","author":"L Munaron","year":"2004","unstructured":"Munaron L, Antoniotti S, Pla AF, Lovisolo D (2004) Blocking Ca2+ entry: a way to control cell proliferation. Curr Med Chem 11(12):1533\u20131543","journal-title":"Curr Med Chem"},{"issue":"2","key":"2771_CR34","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1365-2354.1993.tb00164.x","volume":"2","author":"S Robinson","year":"1993","unstructured":"Robinson S (1993) Principles of chemotherapy. Eur J Cancer Care 2(2):55\u201365","journal-title":"Eur J Cancer Care"},{"issue":"8","key":"2771_CR35","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/j.1748-5827.2006.00045.x","volume":"47","author":"A Baldi","year":"2006","unstructured":"Baldi A, Colloca E, Spugnini E (2006) Lomustine for the treatment of gastrointestinal mast cell tumour in a dog. J Small Anim Pract 47(8):465\u2013467","journal-title":"J Small Anim Pract"},{"issue":"1","key":"2771_CR36","first-page":"302","volume":"295","author":"RL Martin","year":"2000","unstructured":"Martin RL, Lee J-H, Cribbs LL, Perez-Reyes E, Hanck DA (2000) Mibefradil block of cloned T-type calcium channels. J Pharmacol Exp Ther 295(1):302\u2013308","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"2771_CR37","doi-asserted-by":"publisher","first-page":"439","DOI":"10.4062\/biomolther.2017.223","volume":"26","author":"J-W Kim","year":"2018","unstructured":"Kim J-W, Oh HA, Lee SH, Kim KC, Eun PH, Ko MJ, Gonzales ELT, Seung H et al (2018) T-type calcium channels are required to maintain viability of neural progenitor cells. Biomol Ther 26(5):439","journal-title":"Biomol Ther"},{"issue":"4","key":"2771_CR38","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1111\/j.1476-5381.2012.01852.x","volume":"166","author":"Y Zhang","year":"2012","unstructured":"Zhang Y, Zhang J, Jiang D, Zhang D, Qian Z, Liu C, Tao J (2012) Inhibition of T-type Ca2+ channels by endostatin attenuates human glioblastoma cell proliferation and migration. Br J Pharmacol 166(4):1247\u20131260","journal-title":"Br J Pharmacol"},{"issue":"1","key":"2771_CR39","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.canlet.2008.03.032","volume":"267","author":"JT Taylor","year":"2008","unstructured":"Taylor JT, Huang L, Pottle JE, Liu K, Yang Y, Zeng X, Keyser BM, Agrawal KC et al (2008) Selective blockade of T-type Ca2+ channels suppresses human breast cancer cell proliferation. Cancer Lett 267(1):116\u2013124","journal-title":"Cancer Lett"},{"issue":"1","key":"2771_CR40","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ceca.2007.03.006","volume":"43","author":"F Lu","year":"2008","unstructured":"Lu F, Chen H, Zhou C, Liu S, Guo M, Chen P, Zhuang H, Xie D et al (2008) T-type Ca2+ channel expression in human esophageal carcinomas: a functional role in proliferation. Cell Calcium 43(1):49\u201358","journal-title":"Cell Calcium"},{"issue":"15","key":"2771_CR41","doi-asserted-by":"publisher","first-page":"e14046","DOI":"10.1200\/JCO.2018.36.15_suppl.e14046","volume":"36","author":"NH Lester-Coll","year":"2018","unstructured":"Lester-Coll NH, Supko JG, Kluytenaar J, Pavlik KF, Yu JB, Moliterno J et al (2018) Mibefradil dihydrochloride with hypofractionated radiation for recurrent glioblastoma: A phase I dose expansion trial. J Clin Oncol 36(15):e14046\u2013e14046","journal-title":"J Clin Oncol"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-022-02771-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-022-02771-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-022-02771-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T19:13:01Z","timestamp":1668107581000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-022-02771-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,4]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["2771"],"URL":"https:\/\/doi.org\/10.1007\/s12035-022-02771-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-767880\/v1","asserted-by":"object"}]},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,4]]},"assertion":[{"value":"5 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}